Hayward, Calif.–based Pulse Biosciences’ study evaluates its novel Cardiac Surgery System for ablating cardiac tissue to treat AFib. The Cardiac Surgery System received FDA breakthrough device designation last month.

The technology utilizes Pulse Biosciences’ CellFX nanosecond pulsed field ablation (nsPFA) technology and percutaneous electrode system, which the FDA cleared earlier this year. It enables the ablation of soft tissue in percutaneous and intraoperative surgical procedures.

This system, which features a surgical clamp, produces durable, continuous transmural ablation lesions during cardiac surgery. The bipolar clamp utilizes the proprietary nsPFA technology.